Roberto J. C. Fonseca; Gustavo R. C. Santos; Paulo A. S. Mourão
Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho and Programa de Glicobiologia, Instituto de Bioquímica Médica, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Sulfated polysaccharides from marine invertebrates have welldefined structures and constitute a reliable class of molecules for structure-activity relationship studies. We tested the effects of two of these polysaccharides, namely a sulfated fucan and a fucosylated chondroitin sulfate, on coagulation, thrombosis and bleeding. The compounds share similar 2,4-disulfated fucose units, which are required for high anticoagulant activity in this class of polymer. These residues occur either as branches in fucosylated chondroitin sulfate or as components of the linear chain in the sulfated fucan. These polysaccharides possess anticoagulant activity but differ significantly in their mechanisms of action. The fucosylated chondroitin sulfate inhibits thrombin by heparin cofactor II, whereas sulfated fucan inhibits thrombin by both antithrombin and heparin cofactor II. In addition, these polysaccharides also have serpin-independent anticoagulant activities. Fucosylated chondroitin sulfate, but not sulfated fucan, activates factor XII. As a result of the complex anticoagulant mechanism, the invertebrate polysaccharides differ in their effects on experimental thrombosis. For instance, the sulfated fucan inhibits venous thrombosis at lower doses than fucosylated chondroitin sulfate. In contrast, fucosylated chondroitin sulfate is significantly more potent than sulfated fucan in arterial thrombosis. Finally, fucosylated chondroitin sulfate increases bleeding, while sulfated fucan has only a discrete effect. In conclusion, the location of 2,4-disulfated fucose units in the polysaccharide chains dictates the effects on coagulation, thrombosis and bleeding.
heparin, Sulfated fucans, fucoidan, anticoagulant activity, invertebrate, antithrombotic activity
M. A. Lima (1, 2), C. Viskov (3), F. Herman (3), A. L. Gray (4), E. H. C. de Farias (1), R. P. Cavalheiro (1), G. L. Sassaki (5), D. Hoppensteadt (4), J. Fareed (4), H. B. Nader (1)
Thromb Haemost 2013 109 3: 471-478
Elaine Gray1, Barbara Mulloy1, Trevor W. Barrowcliffe1,2
Thromb Haemost 2008 99 5: 807-818
Fábio R. Melo, Paulo A. S. Mourão
Thromb Haemost 2008 99 3: 531-538
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...